本文關(guān)鍵詞：大環(huán)內(nèi)酯類藥物治療慢性鼻-鼻竇炎的Meta分析　出處：《中國(guó)耳鼻咽喉頭頸外科》2016年11期 　論文類型：期刊論文

  更多相關(guān)文章： 鼻竇炎 大環(huán)內(nèi)酯類 Meta分析

【摘要】：目的系統(tǒng)評(píng)價(jià)大環(huán)內(nèi)酯類藥物治療慢性鼻-鼻竇炎(CRS)的臨床療效及安全性。方法計(jì)算機(jī)檢索Pub Med、OVID、EMBASE、中國(guó)學(xué)術(shù)期刊全文數(shù)據(jù)庫(kù)、萬(wàn)方數(shù)據(jù)庫(kù)中關(guān)于大環(huán)內(nèi)酯類藥物治療CRS的隨機(jī)對(duì)照試驗(yàn)(Randomized controlled trials,RCT),同時(shí)追索納入文獻(xiàn)的參考文獻(xiàn)。檢索年限均從建庫(kù)檢索至2016年1月。由2名評(píng)價(jià)員獨(dú)立篩查文獻(xiàn),對(duì)納入的文獻(xiàn)進(jìn)行質(zhì)量評(píng)價(jià),并提取資料,對(duì)符合質(zhì)量標(biāo)準(zhǔn)的RCTs進(jìn)行Meta分析,比較大環(huán)內(nèi)酯類藥物組與安慰劑組鼻腔鼻竇結(jié)局評(píng)分(sinonasal outcome test,SNOT)、患者反應(yīng)量表評(píng)分和安全性評(píng)估。統(tǒng)計(jì)學(xué)分析采用Rev Man5.3軟件。結(jié)果共納入3篇RCTs,Met a分析結(jié)果顯示,長(zhǎng)期低劑量應(yīng)用大環(huán)內(nèi)酯類藥物第24周時(shí)患者SNOT評(píng)分(WMD=-0.43,P=0.03)降低,第12周時(shí)SNOT變化(WMD=-0.23,P=0.25)和患者反應(yīng)量表評(píng)分變化(WMD=-0.40,P=0.28)無統(tǒng)計(jì)學(xué)意義。大環(huán)內(nèi)酯類藥物的不良反應(yīng)發(fā)生率與安慰劑組相似。結(jié)論長(zhǎng)期低劑量應(yīng)用大環(huán)內(nèi)酯類藥物不能明顯改善CRS患者的臨床癥狀,其不良反應(yīng)發(fā)生率與對(duì)照組相近。
[Abstract]:Objective to evaluate the clinical efficacy and safety of macrolides in the treatment of chronic rhinosinusitis. Chinese academic journal full-text database, Wanfang database on macrolides drug treatment of CRS randomized controlled trial of controlled trials. The retrieval years were from the construction of the database to January 2016. Two evaluators independently screened the literature, evaluated the quality of the included documents, and extracted the data. Meta analysis was performed on RCTs that met the quality standard. The sinonasal outcome test was compared between the macrolides group and the placebo group. Rev Man5.3 software was used for statistical analysis. The results were included in the results of 3 RCTsMet a analysis. The SNOT score of patients with macrolides was decreased at the 24th week (WMD-0.43P0. 03) and the change of SNOT at the 12th week (WMD-0.23). (P = 0.25) and WMD-0.40. The incidence of adverse reactions of macrolides was similar to that of placebo group. Conclusion long term low dose of macrolides can not improve the clinical symptoms of patients with CRS. The incidence of adverse reactions was similar to that of the control group.
【作者單位】： 山西醫(yī)科大學(xué)第一醫(yī)院耳鼻咽喉頭頸外科;
【分類號(hào)】：R765
【正文快照】： Ef f icacy of macrol ides in the treatment of chronicrhinosinusitis:A meta-analysisNIU Huihui,CHAI XiangbinDepartment of Otolaryngology Head and Neck Surgery,the First Hospital of Shanxi Medical University,Taiyuan,Shanxi,030000,China慢性鼻-鼻竇炎(CRS)是，

本文編號(hào)：1367984